MOD Awardees Profile プロフィール
氏名：増田 紘子
Name：Hiroko Masuda
現所属：昭和大学乳腺外科
Current working institution (Department / Section)：Department of Breast Surgical Oncology/ Showa University
留学時所属：岡山大学呼吸器・乳腺内分泌外科
Institution where employed when he/she went abroad for MOD：Okayama University / Department of General Thoracic Surgery and Breast and Endocrinological Surgery
Professor Naoto T Ueno出身大学：高知大学
Graduate school：Kochi University
研修先(MOD institution)：The University of Texas MD Anderson Cancer Center
研究室(Laboratory at MOD institution)：Department of Breast Medical Oncology
メンター(Mentor)：Professor Naoto T Ueno
研修期間(Dates)：6/1/2011-3/30/2013
研究テーマ(Research theme)：
To investigate the Triple negative breast cancer heterogeneity.
At MD Anderson, I have conducted translational research focused on triple-negative breast cancer (TNBC) and inflammatory breast cancer (IBC). I have performed gene expression analyses to identify molecular subtypes of TNBC that are refining our understanding of breast cancer biology and enabling development of targeted therapy. We now develop the TNBC classification tool with the gene analysis company named Insight Genetics.
研究成果(Research result) -Article/Presentation at the congress論文・学会発表-：as of August, 2018
2011年6月から2年弱、MDアンダーソンがんセンター乳腺腫瘍科にて研修を行いました。
乳腺外科医として実臨床を行う中で、術前化学療法に対して抵抗性を示すトリプルネガティブ乳がんに対し、有効な分子標的薬の開発に携わりたいと思うようになり、上野直人教授のもとで、トリプルネガティブ乳がん、炎症性乳がんといった難治性乳がんに対する研究の機会をいただきました。
網羅的遺伝子解析を行うことで、トリプルネガティブ乳がんを細分化し、それぞれの生物学的特徴を解明し、その特徴に沿った新規治療戦略の構築を試みました。遺伝子解析が積極的に行われるようになってすでに15年以上たち、なかなか皆さんが感じられるような治療の進歩が得られていませんが、今年、トリプルネガティブ乳がんに多いBRCA1/2遺伝子変異陽性乳がん患者さんに対する新薬が承認されましたし、また期待できる新薬、分子標的薬が現在試験中です。
個人的にはトリプルネガティブの細分化を行い、帰国後、MDアンダーソンと共同研究を続け、日本の方々のサンプルでの解析も行っております。そして、ようやく細分化診断ツールの開発、臨床応用まで手が届きそうなところまで進展してきました。少しずつ少しずつ、牛の歩みも千里を目指し、前進しております。
皆さんが一歩一歩、後押ししてくださったこのMｙoncology dream Awardも2020年で10周年を迎えます。素晴らしい仲間の輪が広がっています。皆さんに還元できるよう、これからも日々精進して参りたいと思っています。
1. Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT. Reverse Phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtype. Oncotarget 2017:8:70481-70495 July
2. Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT.
Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. Breast Cancer Res Treat. 2018 Jun 18.
3. Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA Jr, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT.EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget. 2017 Jul 4;8(40):67904-67917.
4. Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul;164(1):57-67.
5. Sawada T, Akashi S, Nakamura S, Kuwayama T, Enokido K, Yoshida M, Hashimoto R, Ide T, Masuda H, Taruno K, Oyama H, Takamaru T, Kanada Y, Ikeda M, Kosugi N, Sato H, NakayamaS, Ata A, Tonouchi Y, Sakai H, Matsunaga Y, Matsutani A. Digital volumetric measurement of mammographic density and the risk of overlooking cancer in Japanese women.
Breast Cancer. 2017 Sep;24(5):708-713.
6. Kogawa T, Fouad TM, Liu DD, Wu J, Shen Y, Masuda H, Fujii T, Chavez-MacGregor M, Alvarez RH, Hortobágyi GN, Valero V, Ueno NT. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
Oncologist. 2016 Jan;21(1):21-7.
7. Kai K, Kondo K, Wang X, Xie X, Pitner MK, Reyes ME, Torres-Adorno AM, Masuda H, Hortobagyi GN, Bartholomeusz C, Saya H, Tripathy D, Sen S, Ueno NT.
Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. Mol Cancer Ther. 2015 Dec;14(12):2687-99.
8. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.
Breast Cancer Res Treat. 2015 Jul;152(2):407-16.
9. Wolfe AR, Atkinson RL, Reddy JP, Debeb BG, Larson R, Li L, Masuda H, Brewer T, Atkinson BJ, Brewster A, Ueno NT, Woodward WA. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1072-80.
10. Kogawa T, Fouad TM, Wei C, Masuda H, Kai K, Fujii T, El-Zein R, Chavez-MacGregor M, Litton JK, Brewster A, Alvarez RH, Hortobagyi GN, Valero V, Theriault R, Ueno NT.
Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer.
J Cancer. 2015 Jan 22;6(4):310-8.
11. Mego M, Giordano A, De Giorgi U, Masuda H, Hsu L, Giuliano M, Fouad TM, Dawood S, Ueno NT, Valero V, Andreopoulou E, Alvarez RH, Woodward WA, Hortobagyi GN, Cristofanilli M, Reuben JM. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
Breast Cancer Res. 2015 Jan 9;17:2.
12. Masuda H, Brewer TM, Ueno NT et al. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor and HER2-defined subtypes.
Ann Oncol. 25(2):384-91, 2014 Feb
13. Lacerda L, Reddy JP, Liu D, Larson R, Li L, Masuda H, Brewer T, Debeb BG, Xu W, Hortobágyi GN, Buchholz TA, Ueno NT, Woodward WA. Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation.
Stem Cells Transl Med. 2014 Jul;3(7):849-56.
14. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, Pusztai L, Kai K, Kogawa T, Finetti P, Birnbaum D, Dirix L, Woodward WA, Reuben JM, Krishnamurthy S, Symmans W, Van Laere SJ, Bertucci F, Hortobagyi GN, Ueno NT.
Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25;15(6):R112.
15. Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD, Pietenpol JA, Hortobagyi GN, Symmans F, Ueno NT.
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Aug 15
16. Van Laere SJ, Ueno NT, Finetti P, Vermeulen PB, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam PA, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix LY, Reuben JM, Bertucci F. Uncovering the molecular secrets of Inflammatory Breast Cancer biology: An integrated analysis of three distinct Affymetrix gene expression data sets. Clin Cancer Res.2013 Sep 1;19(17):4685-4696. Epub 2013 Feb 8.
17. Masuda H, Brewer TM, Liu DD, Shen Y, Liu P, Iwamoto T, Kai K, Barnett CM, Woodward WA, Reuben JM, Yang P, Hortobagyi GN, Ueno NT. Statin use in primary inflammatory breast
cancer: a cohort study. Br J Cancer. 2013 Jul 23;109(2):318-24.
18. Masuda H, Otsuka F, Matsumoto Y, Takano M, Miyoshi T, Inagaki K, Shien T, Taira N, Makino H, Doihara H. Functional interaction of fibroblast growth factor-8, bone morphogenetic
protein and estrogen receptor in breast cancer cell proliferation. Mol Cell Endocrinol. 2011 Jun 1.
19. Masuda H, Masuda N, Kodama Y, Ogawa M, Karita M, Yamamura J, Tsukuda K, Doihara H, Miyoshi S, Mano M, Makamori S, Tsujinaka T, Predictive factors for the effectiveness of neoadjuvant chemotherapy and prognosis in triple-negative breast cancer patients. Cancer Chemother Pharmacol. 2011 Apr;67(4):911-7.
20. Masuda H, Dongwei Zhang, Chandra Bartholomeusz, Hiroyoshi Doihara, Gabriel N. Hortobagyi, Naoto T. Ueno. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012 Oct,136:331-345
CONFERENCES AND SYMPOSIA
Presentations at International Conferences
Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs)
ASCO Annual Meeting 208
Poster Presentation, Chicago, USA, 3/June-6/June/2018
Comparison of molecular subtypes of triple-negative breast cancer derived from reverse-phase protein arrays and mRNA analysis
Asian Breast Cancer Society Global Breast Cancer Conference,
Poster, Seoul, Korea, 5/Apr-7/Apr/2018
Identify Triple Negative Breast Cancer Subtypes Using
Reverse Phase Protein Arrays(RPPAs)
Asian Breast Cancer Society Global Breast Cancer Conference,
Poster, Jeju Island, Korea, 28/Apr-30/Apr/2016
Classification of molecular subtypes of triple-negative breast cancer using reverse phase protein arrays (RPPAs)
ASCO Annual Meeting 2014
Poster Presentation, Chicago, USA, 30/May-3/June/2014
Differential Pathological Complete Response (pCR) rates after Neoadjuvant
Chemotherapy among Molecular Subtypes of Triple-Negative Breast Cancer.
ASCO Annual Meeting 2013
Oral Presentation, Chicago, USA, 31/May/2013-4/Jun/2013
Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy
San Antonio Breast Cancer Symposium 2013.
Poster Presentation, San Antonio, USA, 4-8/Dec/2013
Response to neoadjuvant systemic therapy (NAST) in inflammatory breast cancer (IBC) according to estrogen receptor (ER) and HER2 expression.
San Antonio Breast Cancer Symposium 2012.
Poster Presentation, San Antonio, USA, 4-8/Dec/2012
Inflammatory breast cancer response to neoadjuvant systemic therapy according
to hormonal receptor and HER2 status.
Third International Inflammatory Breast Cancer Conference 2012.
Oral presentation, Philadelphia, USA, 1-2/Dec/2012
Molecular Comparison of Human Triple-Negative Inflammatory Breast Cancer
(TN-IBC) and Human Triple-Negative Non inflammatory Breast Cancer (TN-non IBC).
ASCO Annual Meeting 2012.
Poster Presentation, Chicago, USA, 1-5/Jun/2012
FgF-8 stimulates breast cancer cell mitosis by regulating BMP and ER actions.
12th St. Gallen International Breast Cancer Conference,
Poster Session, St. Gallen, Switzerland, 16-M19/March/2011
